|Bid||145.00 x 900|
|Ask||154.00 x 800|
|Day's Range||150.50 - 154.97|
|52 Week Range||42.97 - 176.50|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 23, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||189.10|
Sarepta Therapeutics CEO Douglas Ingram discusses the status of his company's drug trials and what's been driving the stock higher this year.
Solid Biosciences (SLDB) incurred a net loss of $17.98 million in the second quarter of 2018, which compares to a net loss of $11.31 million in the second quarter of 2017, translating to a net loss per share of $0.52 in the second quarter of 2018. Its net loss per share was $0.66 in the second quarter of 2017. The decrease in net loss per share was due to an increase in the company’s outstanding shares, which increased from 17.04 million in the second quarter of 2017 to 34.45 million in the second quarter of 2018.
In the second quarter, PTC Therapeutics generated revenues of $68.7 million—compared to $48.0 million in the second quarter of 2017, which reflected ~43% growth YoY (year-over-year). In the first half of 2018, PTC Therapeutics reported net revenues of $124.8 million—compared to $74.5 million in the first half of 2017.
On September 13, PTC Therapeutics’ stock price closed at $47.33, which is ~0.66% growth from the close of $47.02 the previous day.
Sarepta Therapeutics (SRPT) has returned 169.97% YTD (year-to-date). In the second quarter, it reported EPS of -$0.43, surpassing the consensus estimate by $0.46. EXONDYS 51 sales were $73.5 million in the quarter, which is a YoY (year-over-year) rise of 110%. Wall Street analysts have projected a 12-month consensus target price of $188.58, which is a 25.54% rise over its closing price on September 13. By the end of 2018, Sarepta Therapeutics plans to submit a rolling NDA (New Drug Application) to the FDA for golodirsen, an investigational phosphorodiamidate Morpholino oligomer (or PMO) therapy, in Duchenne muscular dystrophy (or DMD) due to deletions in the DMD gene related to exon 53 skipping.
Sarepta Therapeutics (SRPT) is a commercial-stage biopharmaceutical company focused on developing unique RNA-targeted therapeutics, gene therapy, and other genetic products targeted for rare neuromuscular diseases. Sarepta’s first product on the market, Exondys 51 (eteplirsen), is indicated for treating Duchenne muscular dystrophy (or DMD). In June, the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a negative opinion for eteplirsen.
Sarepta Therapeutics (SRPT) incurred a net loss of $109.27 million in the second quarter of 2018 compared to a net loss of $63.05 million in Q2 2017. Its net loss per share was $1.15 in the second quarter of 2017. Despite the surge in revenues, Sarepta’s net loss widened due to higher operating expenses, which increased from $98.35 million in the second quarter of 2017 to $176.96 million in the second quarter of 2018.
Gene therapy involves repairing or replacing disease-causing genes. Investor interest in gene therapy stocks has remained buoyant throughout 2018. According to Allied Market Research, the gene therapy market is expected to grow at a 33.3% CAGR (compound annual growth rate) to $4.4 billion by 2023.
The indices are being jerked around on some news headlines today. These headlines trigger very obvious "buy" algorithms that took the indices into positive territory. Within about 30 minutes the move was totally reversed but some buyers have remained and have the indices off the lows.
The indices have been slowly drifting lower after a gap up open. Early breadth was around 3 to 1 positive but its now down to around 4-3 positive. The bulls are not producing much positive momentum but the bears are doing an even worse job of producing negative momentum.
Sarepta Therapeutics CEO Doug Ingram wants the company to start giving its Duchenne muscular dystrophy gene therapy to children in the approval trial by the end of this year. "We have a big ambition to potentially be to the community within two years thereafter," he says. Sarepta Therapeutics CEO Doug Ingram told CNBC on Friday he has a "big ambition" to get the company's Duchenne muscular dystrophy gene therapy to patients as quickly as possible.
In the second quarter, Spectrum Pharmaceuticals (SPPI) generated net revenues of $24.2 million compared to $34.3 million in Q2 2017. In the first half of the year, Spectrum Pharmaceuticals reported net revenues of $54.7 million compared to $63.4 million in H1 2017.
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Sarepta Therapeutics, Inc. (SRPT), a global biopharmaceutical company focused on the discovery and development of precision genetic medicines for the treatment of rare neuromuscular and other rare diseases, will ring Nasdaq’s Opening Bell today in recognition of World Duchenne Awareness Day (WDAD), an observance recognized annually around the world on September 7. “We are fully committed to our mission of bringing a longer, richer life to patients with Duchenne muscular dystrophy. Along with other healthcare companies dedicated to fighting this disease, we believe we may stand at the threshold of a new frontier, unlocking the potential of precision genetic medicine to make a profound difference in the lives of individuals living with rare genetic disease,” said Doug Ingram, Sarepta’s president and chief executive officer.
The Street has a lot of faith in Sarepta Therapeutics, Inc. (NASDAQ: SRPT ). The biotech firm notched its 20th bullish rating Thursday to further neutralize a lone Hold. The Rating Credit Suisse analysts ...
After the breakout move on August 27 and some strong upside follow-through it isn't too surprising that the market is finally pulling back. So far it is fairly mild action but breadth is running 2 advancers for every 5 decliners so it is broad selling.
Morgan Stanley 16th Annual Global Healthcare Conference on Wednesday, September 12, 2018 at 4:15 p.m. E.T. The fireside chat will be held at the Grand Hyatt New York in New York City. Janney Montgomery Scott Healthcare Conference on Tuesday, September 18, 2018 at 8:15 a.m. E.T. The fireside chat will be held at the Union League Club in New York City. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
Sarepta Therapeutics, Inc. (SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, granted equity awards on August 31, 2018, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to twenty-two individuals hired by Sarepta in August 2018. The employees received, in the aggregate, options to purchase 80,495 shares of Sarepta's common stock.
Articles published in Nature and other scientific journals this year have raised doubts about the safety of technologies like CRISPR/Cas9 that cut into DNA, with studies indicating that the approach could cause unwanted genetic changes, immune responses or tumors. Exonics Therapeutics believes it has hit on the solution.
You don't have to be Sigmund Freud to understand the psychology here. The folks that have missed out or underperformed recently are afraid they will miss out again so they are quick to buy weakness. In addition to that psychology there also is the inclination for many institutional investors to only buy weakness.
Scholar Rock Holding Corp. (srrk) shares dropped 11% in active Thursday trade after Pfizer Inc. (pfe) announced it plans to stop two ongoing clinical trials for a similar rare-disease drug. "Although SRRK has not formally announced its strategy in DMD, we see the setting as ideal for lead candidate SRK-015, which could complement the gene therapies that are in development from Sarepta (srpt) Solid Bio (sldb) and Pfizer...Neither SRPT and SLDB have anti-myostatin programs of their own," he said, adding that SRK-015 "should be more selective and provide an improved therapeutic window relative to programs like doma which target mature myostatin." Phase 1 safety data for the therapy could be available before the end of the year, providing a catalyst for Scholar Rock shares, according to Nierengarten.
Pfizer Inc. (pfe) is ending ongoing research for a Duchenne muscular dystrophy drug after finding that the evidence "did not support a significant treatment effect," the company said on Thursday. Shares slumped 0.5% premarket, while shares of DMD drugmaker Sarepta Therapeutics Inc. (srpt) rose 0.9%. Pfizer plans to keep reviewing trial data "to see if there is a place for this medicine in muscular diseases," said Seng Cheng, senior vice president and chief scientific officer, Pfizer Rare Disease Research Unit.
NEW YORK, NY / ACCESSWIRE / August 30, 2018 / Wall Street extended gains with the Dow Jones closing at its highest since February, as market participants cheers on a possibility of a trilateral North American ...
This decade’s stock market is filled with small baby-boomer investors who hope to make one last killing so they can retire in comfort. It was a company called Sarepta Therapeutics (NASDAQ:SRPT). The value of SRPT stock has increased 400% over the last two years.